Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

Submitted by Anonymous on

Original Article Share on Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLCAuthors: Pasi A. Jänne, M.D., Ph.D., David Planchard, M.D., Ph.D., Kunihiko Kobayashi, M.D., Ph.D., James Chih-Hsin Yang, M.D., Ph.D., Ying Liu, M.D., Natalia Valdiviezo, M.D., Tae Min Kim,...

Case Report: Short-term disease control with subsequent icotinib therapy in EGFR L858R/C797S, T790M-negative lung adenocarcinoma after osimertinib resistance

Submitted by Anonymous on

Abstract Osimertinib resistance, particularly EGFR C797S without T790M, lacks established treatment strategies. We report a 71-year-old woman with stage IVB lung adenocarcinoma harboring EGFR L858R (T790M-negative) who received first-line osimertinib for 29 months until progression. Post-progression ctDNA revealed L858R/C797S (T790M-negative)...

Multi-task deep learning model for predicting EGFR mutation status in NSCLC

Submitted by Anonymous on

Multi-task DL for predicting EGFR mutation status Epidermal growth factor receptor (EGFR) mutation status is a critical biomarker in the management of non-small cell lung cancer (NSCLC), playing an essential role in selecting patients for EGFR-targeted treatment. With advancements in...

Time-resolved phenotypic profiling maps EGFR and c-Met trafficking signatures

Submitted by Anonymous on

The epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met/MET) are receptor tyrosine kinases (RTKs) whose signalling depends on endocytic routing, and impaired down-regulation can drive tumour progression and therapy resistance, including MET-driven bypass of EGFR inhibition. However,...

Predicting response to immune checkpoint inhibitor plus chemotherapy in EGFR-mutant lung adenocarcinoma following first-generation TKI resistance: a multicenter deep learning study

Submitted by Anonymous on

BackgroundPatients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma who develop resistance to first-generation tyrosine kinase inhibit 2 Materials and methods2.1 Study participants The patient selection process is shown in Figure 1. The initially identified screening cohort consisted of 750...

Inhibitory effects of 2′-nitroflavone and apigenin on EGFR signaling in breast cancer cells

Submitted by Anonymous on

The epidermal growth factor receptor (EGFR) is frequently dysregulated in certain cancers, including breast cancer. Gefitinib, an EGFR tyrosine kinase inhibitor (TKI) used in non-small cell lung cancer, was proposed for breast cancer treatment. The use of TKI in combination...

Association between vertebral endplate defects and low back pain: an integrative omics study revealing the role of lipotoxicity-induced EGFR/COX-2 signalling

Submitted by Anonymous on

AbstractStudy design Retrospective study. Objective To investigate the association between endplate defects and patient-reported outcomes and to further clarify the role of lipotoxicity-induced EGFR/COX-2 signalling in the pathogenesis of low back pain. Summary of background data As the hub of...

Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis

Submitted by Anonymous on

BackgroundPatients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) inevitably develop resistance to EGFR-tyrosine kina Abstract Background: Patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) inevitably develop resistance to EGFR-tyrosine kinase inhibitors (TKIs)....

Murine autoantigen-specific type 1 regulatory T cells promote oligodendrogenesis through amphiregulin-EGFR signaling

Submitted by Anonymous on

AbstractMultiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that results from oligodendrocyte loss and multifocal demyelination of the CNS white matter. Current therapies can suppress the progression of CNS inflammation but do not actively promote...

Subscribe to Newsfeed